- Triacetylganciclovir
-
- $0.00 / 25KG
-
2025-12-01
- CAS:86357-14-4
- Min. Order: 1KG
- Purity: 98.0%
- Supply Ability: 10000KGS
|
| | N-[9-[[2-(Acetyloxy)-1-[(acetyloxy)methyl]ethoxy]methyl]-6,9-dihydro-6-oxo-1H-purin-2-yl]acetamide Basic information |
| | N-[9-[[2-(Acetyloxy)-1-[(acetyloxy)methyl]ethoxy]methyl]-6,9-dihydro-6-oxo-1H-purin-2-yl]acetamide Chemical Properties |
| Melting point | 174 °C | | density | 1.50 | | storage temp. | Sealed in dry,Room Temperature | | solubility | DMSO (Slightly), Methanol (Slightly, Heated) | | pka | 8.74±0.20(Predicted) | | form | Solid | | color | White to Pale Beige | | CAS DataBase Reference | 86357-14-4(CAS DataBase Reference) |
| | N-[9-[[2-(Acetyloxy)-1-[(acetyloxy)methyl]ethoxy]methyl]-6,9-dihydro-6-oxo-1H-purin-2-yl]acetamide Usage And Synthesis |
| Chemical Properties | Light Brown Solid | | Uses | Ganciclovir derivative. | | Synthesis | The general procedure for the synthesis of 2-((2-acetylamino-6-oxo-1H-purin-9(6H)-yl)methoxy)propane-1,3-diyl diacetate from 2-(acetyloxymethoxy)-1,3-propanediol diacetate and N-(9-acetyloxy-6-oxo-6,9-dihydro-1H-purin-2-yl)acetamide is as follows: first, 50.0 g ( 0.21 mol, 1.0 eq.) of 20.0-diacetylguanine, 104.2 g (0.42 mol, 2.0 eq.) of 1,3-diacetoxy-2-(acetyloxymethoxy)propane and 3.0 g (0.021 mol, 0.1 eq.) of boron trifluoride ether compounds were mixed with 200 g of N,N-dimethylformamide in a microwave reactor. The reaction mixture was heated to 100 °C and maintained at this temperature for 10 hours. Upon completion of the reaction, the solvent was removed by distillation under reduced pressure and the mixture was cooled to room temperature. Subsequently, 450 g of ethyl acetate was added to the mixture and refluxed for 1 hour, after which the temperature was reduced to 0-5 °C and maintained for 1 hour. After filtration and drying process, 68.3 g of triacetyl ganciclovir compound (2) was obtained in 85.3% yield and 95.6% purity, while 3.1% of compound (3) was obtained. | | References | [1] Patent: CN108467396, 2018, A. Location in patent: Paragraph 0030; 0031; 0036; 0037; 0040; 0041; 0044; 0045 |
| | N-[9-[[2-(Acetyloxy)-1-[(acetyloxy)methyl]ethoxy]methyl]-6,9-dihydro-6-oxo-1H-purin-2-yl]acetamide Preparation Products And Raw materials |
|